Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Influenza

Free Subscription 19.02.2024 7 Antiviral Res 5 BMJ 1 Epidemiol Infect 2 J Clin Microbiol 1 J Infect Dis 4 J Virol 1 JAMA 4 Lancet 2 PLoS Comput Biol 21 PLoS One 17 Vaccine 2 Virus Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Antiviral Res

1. ZHANG X, Xia Y, Li P, Wu Z, et al
   Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus.
   Antiviral Res. 2024 Feb 11:105822. doi: 10.1016/j.antiviral.2024.105822.
   PubMed         Abstract available
   
   
2. IZMAILYAN R, Matevosyan M, Khachatryan H, Shavina A, et al
   Discovery of new antiviral agents through artificial intelligence: In vitro and in vivo results.
   Antiviral Res. 2024;222:105818.
   PubMed         Abstract available
   
   
3. BOUZIDI HS, Driouich JS, Klitting R, Bernadin O, et al
   Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
   Antiviral Res. 2024 Jan 23:105814. doi: 10.1016/j.antiviral.2024.105814.
   PubMed         Abstract available
   
   
4. IDRIS A, Supramaniam A, Tayyar Y, Kelly G, et al
   An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.
   Antiviral Res. 2024;222:105815.
   PubMed         Abstract available
   
   
5. RICHTER M, Doring K, Blaas D, Riabova O, et al
   Molecular mechanism of rhinovirus escape from the Pyrazolo[3,4-d]pyrimidine capsid-binding inhibitor OBR-5-340 via mutations distant from the binding pocket: Derivatives that brake resistance.
   Antiviral Res. 2024;222:105810.
   PubMed         Abstract available
   
   
6. GOVEDNIK T, Lainscek D, Kuhar U, Lachish M, et al
   TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences.
   Antiviral Res. 2024 Jan 9:105806. doi: 10.1016/j.antiviral.2024.105806.
   PubMed         Abstract available
   
   
7. LOAIZA RA, Ramirez RA, Sepulveda-Alfaro J, Ramirez MA, et al
   A molecular perspective for the development of antibodies against the human respiratory syncytial virus.
   Antiviral Res. 2024;222:105783.
   PubMed         Abstract available
   
   

   
   BMJ

8. MCGREGOR G, Sandhu H, Bruce J, Sheehan B, et al
   Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial.
   BMJ. 2024;384:e076506.
   PubMed         Abstract available
   
   
9. HINMAN RS, Maher CG
   Rehabilitation for post-covid-19 condition.
   BMJ. 2024;384:q20.
   PubMed        
   
   
10. IACOBUCCI G
    Long covid: Online rehabilitation can improve quality of life, study reports.
    BMJ. 2024;384:q346.
    PubMed        
    
    
11. 
    Seven days in medicine: 31 Jan to 6 Feb 2024.
    BMJ. 2024;384:q299.
    PubMed        
    
    
12. CIPRIANO CB, Kadakia KT, Chokshi DA
    Is the US prepared for the next pandemic? No, but it could be.
    BMJ. 2024;384:q332.
    PubMed        
    
    

    
    Epidemiol Infect

13. YAMAYOSHI S, Nagai E, Mitamura K, Hagihara M, et al
    Seroprevalence of severe acute respiratory syndrome coronavirus 2 N antibodies between December 2021 and march 2023 in Japan.
    Epidemiol Infect. 2024;152:e24.
    PubMed         Abstract available
    
    

    
    J Clin Microbiol

14. DURANT TJS, Peaper DR
    Retrospective evaluation of clinical decision support for within-laboratory optimization of SARS-CoV-2 NAAT workflow.
    J Clin Microbiol. 2024;62:e0078523.
    PubMed         Abstract available
    
    
15. PFAU B, Opsahl J, Crew R, Best S, et al
    Tiny swabs: nasal swabs integrated into tube caps facilitate large-scale self-collected SARS-CoV-2 testing.
    J Clin Microbiol. 2024;62:e0128523.
    PubMed         Abstract available
    
    

    
    J Infect Dis

16. AMINISANI N, Wood T, Jelley L, Wong C, et al
    The burden of HMPV and influenza associated hospitalizations in adults in New Zealand, 2012-2015.
    J Infect Dis. 2024 Feb 13:jiae064. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Virol

17. NIE L, Huang Y, Cheng Z, Luo H, et al
    An intranasal influenza virus vector vaccine protects against Helicobacter pylori in mice.
    J Virol. 2024 Feb 15:e0192323. doi: 10.1128/jvi.01923.
    PubMed         Abstract available
    
    
18. ZENG J, Du F, Xiao L, Sun H, et al
    Spatiotemporal genotype replacement of H5N8 avian influenza viruses contributed to H5N1 emergence in 2021/2022 panzootic.
    J Virol. 2024 Feb 15:e0140123. doi: 10.1128/jvi.01401.
    PubMed         Abstract available
    
    
19. THOMAS MN, Zanella GC, Cowan B, Caceres CJ, et al
    Nucleoprotein reassortment enhanced transmissibility of H3 1990.4.a clade influenza A virus in swine.
    J Virol. 2024 Feb 14:e0170323. doi: 10.1128/jvi.01703.
    PubMed         Abstract available
    
    
20. KATAYAMA M, Murakami S, Ishida H, Matsugo H, et al
    Antigenic commonality and divergence of hemagglutinin-esterase-fusion protein among influenza D virus lineages revealed using epitope mapping.
    J Virol. 2024 Feb 12:e0190823. doi: 10.1128/jvi.01908.
    PubMed         Abstract available
    
    

    
    JAMA

21. RAGLOW Z, Malani PN, Petty LA
    Outpatient Treatment for COVID-19.
    JAMA. 2023 Aug 16. doi: 10.1001/jama.2023.16666.
    PubMed        
    
    

    
    Lancet

22. DELFRAISSY JF, Horgan M, Molbak K, Simon FS, et al
    Scientific advisory councils in the COVID-19 response.
    Lancet. 2023 Oct 12:S0140-6736(23)01846-9. doi: 10.1016/S0140-6736(23)01846.
    PubMed        
    
    
23. 
    Undervaccination and severe COVID-19 outcomes: meta-analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales.
    Lancet. 2024 Jan 12:S0140-6736(23)02467-4. doi: 10.1016/S0140-6736(23)02467.
    PubMed         Abstract available
    
    
24. GULLIFORD MC, Steves CJ
    Access to COVID-19 vaccination and COVID-19-related hospital admissions and mortality.
    Lancet. 2024 Jan 12:S0140-6736(23)02622-3. doi: 10.1016/S0140-6736(23)02622.
    PubMed        
    
    
25. ADERINTO N, Olatunji G, Kokori E
    Health implications of GSK's departure from Nigeria.
    Lancet. 2024;403:526-527.
    PubMed        
    
    

    
    PLoS Comput Biol

26. VAN BOVEN M, van Dorp CH, Westerhof I, Jaddoe V, et al
    Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study.
    PLoS Comput Biol. 2024;20:e1011832.
    PubMed         Abstract available
    
    
27. CHAN LYH, Ro G, Midtbo JE, Di Ruscio F, et al
    Modeling geographic vaccination strategies for COVID-19 in Norway.
    PLoS Comput Biol. 2024;20:e1011426.
    PubMed         Abstract available
    
    

    
    PLoS One

28. LAOR T
    Public and commercial more of the same? The characteristics of the opening monologues of public and commercial channels during the COVID-19 pandemic.
    PLoS One. 2024;19:e0293172.
    PubMed         Abstract available
    
    
29. GONG Z, Wang Y, Li M
    Determining the drivers of global innovation under COVID-19: An FSQCA approach.
    PLoS One. 2024;19:e0295403.
    PubMed         Abstract available
    
    
30. ROSENBERG A, Puglisi LB, Thomas KA, Halberstam AA, et al
    "It's just us sitting there for 23 hours like we done something wrong": Isolation, incarceration, and the COVID-19 pandemic.
    PLoS One. 2024;19:e0297518.
    PubMed         Abstract available
    
    
31. MCCABE EM, Luk JW, Stangl BL, Schwandt ML, et al
    Exercising healthy behaviors: A latent class analysis of positive coping during the COVID-19 pandemic and associations with alcohol-related and mental health outcomes.
    PLoS One. 2024;19:e0297060.
    PubMed         Abstract available
    
    
32. BOSTAN ALI W, Olayinka JA, Alam MM, Immelman A, et al
    Assessing economic implications for micro, small and medium enterprises in Thailand post Covid-19 lockdown.
    PLoS One. 2024;19:e0294890.
    PubMed         Abstract available
    
    
33. GORGELS KMF, van Iersel SCJL, Keijser SFA, Hoebe CJPA, et al
    Estimating infection prevalence using the positive predictive value of self-administered rapid antigen diagnostic tests: An exploration of SARS-CoV-2 surveillance data in the Netherlands from May 2021 to April 2022.
    PLoS One. 2024;19:e0298218.
    PubMed         Abstract available
    
    
34. SHIROSHITA A, Gebretsadik T, Wu P, Kubilay NZ, et al
    Association between age of respiratory syncytial virus infection hospitalization and childhood asthma: A systematic review.
    PLoS One. 2024;19:e0296685.
    PubMed         Abstract available
    
    
35. MORENO-JUSTE A, Poblador-Plou B, Ortega-Larrode C, Laguna-Berna C, et al
    Mental health and risk of death and hospitalization in COVID-19 patients. Results from a large-scale population-based study in Spain.
    PLoS One. 2024;19:e0298195.
    PubMed         Abstract available
    
    
36. CHEN TL, Chou EP, Chen MY, Hsieh F, et al
    Unraveling implicit human behavioral effects on dynamic characteristics of Covid-19 daily infection rates in Taiwan.
    PLoS One. 2024;19:e0298049.
    PubMed         Abstract available
    
    
37. CILDOZ M, Gaston M, Frias L, Garcia-Vicuna D, et al
    Early detection of new pandemic waves. Control chart and a new surveillance index.
    PLoS One. 2024;19:e0295242.
    PubMed         Abstract available
    
    
38. ASAMOAH I, Adusei-Poku M, Vandyck-Sey P, Steele-Dadzie A, et al
    COVID-19 in patients presenting with malaria-like symptoms at a primary healthcare facility in Accra, Ghana.
    PLoS One. 2024;19:e0298088.
    PubMed         Abstract available
    
    
39. VAN DUSEN J, LeBlanc H, Nastasi N, Panescu J, et al
    Identification of SARS-CoV-2 variants in indoor dust.
    PLoS One. 2024;19:e0297172.
    PubMed         Abstract available
    
    
40. GUADALUPE-FERNANDEZ V, Martinez-Solanas E, Sabria-Sunye A, Ferrer-Mikoly C, et al
    Investigating epidemiological distribution (temporality and intensity) of respiratory pathogens following COVID-19 de-escalation process in Catalonia, September 2016-June 2021: Analysis of regional surveillance data.
    PLoS One. 2024;19:e0285892.
    PubMed         Abstract available
    
    
41. VEPACHEDU S, Nurzenska A, Lohiniva AL, Hudi AH, et al
    Understanding COVID-19 vaccination behaviors and intentions in Ghana: A Behavioral Insights (BI) study.
    PLoS One. 2024;19:e0292532.
    PubMed         Abstract available
    
    
42. GALUSHKO V, Riabchyk A
    The demand for online grocery shopping: COVID-induced changes in grocery shopping behavior of Canadian consumers.
    PLoS One. 2024;19:e0295538.
    PubMed         Abstract available
    
    
43. MOLONEY K, Lamprea Montealegre JA, Busch Isaksen TM, Kennedy M, et al
    Assessing community-level impacts of and responses to stay at home orders: The King County COVID-19 community study.
    PLoS One. 2024;19:e0296851.
    PubMed         Abstract available
    
    
44. SIM J, Shin J, Lee HJ, Lee Y, et al
    Impact of coronavirus disease 2019 on cancer care: How the pandemic has changed cancer utilization and expenditures.
    PLoS One. 2024;19:e0296808.
    PubMed         Abstract available
    
    
45. ASADI-POOYA AA, Nemati M, Shahisavandi M, Nemati H, et al
    How does COVID-19 vaccination affect long-COVID symptoms?
    PLoS One. 2024;19:e0296680.
    PubMed         Abstract available
    
    
46. CHAPUT J, Becquet V, Bithorel PL, Baril E, et al
    Medication abortion during the COVID-19 pandemic in France: A research based on the French national health insurance database.
    PLoS One. 2024;19:e0295336.
    PubMed         Abstract available
    
    
47. LI L, Sullivan A, Musah A, Stavrianaki K, et al
    Positive and negative emotions during the COVID-19 pandemic: A longitudinal survey study of the UK population.
    PLoS One. 2024;19:e0297214.
    PubMed         Abstract available
    
    
48. RIUS-SALVADOR M, Garcia-Murria MJ, Rusu L, Bano-Polo M, et al
    Cetylpyridinium chloride and chlorhexidine show antiviral activity against Influenza A virus and Respiratory Syncytial virus in vitro.
    PLoS One. 2024;19:e0297291.
    PubMed         Abstract available
    
    

    
    Vaccine

49. OKOLI GN, Righolt CH, Zhang G, Van Caeseele P, et al
    A population-based, province-wide, record-linkage interrupted time series analysis of impact of the universal seasonal influenza vaccination policy on seasonal influenza vaccine uptake among 5-64-year-olds in the province of Manitoba, Canada.
    Vaccine. 2024 Feb 14:S0264-410X(24)00104-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
50. AMDISEN L, Pedersen L, Abildgaard N, Benn CS, et al
    The coverage of influenza vaccination and predictors of influenza non-vaccination in Danish cancer patients: A nationwide register-based cohort study.
    Vaccine. 2024 Feb 12:S0264-410X(24)00155-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
51. VALENTIN J, Ingrao F, Rauw F, Lambrecht B, et al
    Protection conferred by an H5 DNA vaccine against highly pathogenic avian influenza in chickens: The effect of vaccination schedules.
    Vaccine. 2024 Feb 12:S0264-410X(23)01422-6. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    
52. WHITAKER HJ, Hassell K, Hoschler K, Power L, et al
    Influenza vaccination during the 2021/22 season: A data-linkage test-negative case-control study of effectiveness against influenza requiring emergency care in England and serological analysis of primary care patients.
    Vaccine. 2024 Feb 10:S0264-410X(24)00150-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
53. WEI J, Tan TC, Moa AM, MacIntyre CR, et al
    Cost-benefit of influenza vaccination in preventing sudden cardiac arrest amongst Australian adults.
    Vaccine. 2024 Feb 9:S0264-410X(24)00154-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
54. GRIMA AA, Kwong JC, Richard L, Reid J, et al
    The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
    Vaccine. 2024 Jan 17:S0264-410X(24)00023-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
55. GEINITZ H, Silberberger E, Spiegl K, Feichtinger J, et al
    SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients.
    Vaccine. 2024 Jan 20:S0264-410X(24)00004-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
56. MITCHELL MM, Klott A, Scholtes J, Braden BB, et al
    Mixed-methods examination of attitudes and behaviors related to COVID-19 vaccines among parents of children with autism and autistic adults.
    Vaccine. 2024 Jan 19:S0264-410X(24)00013-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
57. HICKEN A, Jones P, Menon A, Rozek LS, et al
    Can endorsement by religious leaders move the needle on vaccine hesitancy?
    Vaccine. 2024 Jan 18:S0264-410X(24)00006-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
58. MEMEDOVICH A, Orr T, Hollis A, Salmon C, et al
    Social network risk factors and COVID-19 vaccination: A cross-sectional survey study.
    Vaccine. 2024 Jan 18:S0264-410X(24)00005-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
59. LEMMER Y, Chapman R, Abolnik C, Smith T, et al
    Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters.
    Vaccine. 2024 Jan 17:S0264-410X(24)00036-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
60. HARALAMBIEVA IH, Monroe JM, Ovsyannikova IG, Warner ND, et al
    Restricted Omicron-specific cross-variant memory B-cell immunity after a 3rd dose/booster of monovalent Wuhan-Hu-1-containing COVID-19 mRNA vaccine.
    Vaccine. 2024 Jan 16:S0264-410X(24)00032-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
61. MCADAM E, Hayashi K, Barker B, Reddon H, et al
    COVID-19 vaccination among young people who use drugs in Vancouver, Canada.
    Vaccine. 2024 Jan 14:S0264-410X(24)00009-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
62. RANDELL M, Sheel M, Dynes M, Li M, et al
    Influence of the COVID-19 pandemic on caregiver beliefs and experiences of routine childhood immunisation in Indonesia.
    Vaccine. 2024;42:812-818.
    PubMed         Abstract available
    
    
63. QURESHI NS, Miller LG, Judge SP, Tran NDT, et al
    Characterizing predictors of COVID-19 vaccine refusal in an urban southern California jail population.
    Vaccine. 2024 Jan 9:S0264-410X(24)00017-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
64. BARZEN G, Rieber F, Stangl K, Hahn K, et al
    mRNA vaccines for COVID-19 are safe and clinically effective in patients with cardiac amyloidosis.
    Vaccine. 2023 Dec 28:S0264-410X(23)01487-1. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    
65. CENAT JM, Moshirian Farahi SMM, Broussard C, Dalexis RD, et al
    The state of COVID-19 vaccine confidence and need in Black individuals in Canada: Understanding the role of sociodemographic factors, health literacy, conspiracy theories, traumatic stressors and racial discrimination.
    Vaccine. 2023 Oct 25:S0264-410X(23)01246-X. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    

    
    Virus Res

66. WANG X, Cheng J, Shen L, Chen M, et al
    Rab5c promotes RSV and ADV replication by autophagy in respiratory epithelial cells.
    Virus Res. 2024;341:199324.
    PubMed         Abstract available
    
    
67. HUANG X, Kantonen J, Nowlan K, Nguyen NA, et al
    Mucosal-Associated Invariant T Cells are not susceptible in vitro to SARS-CoV-2 infection but accumulate into the lungs of COVID-19 patients.
    Virus Res. 2024;341:199315.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.